← Leaderboards
George Yancey Gillespie
Treovir, Inc
$2,001,622
Attributed
$2,001,622
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2020–23$2M$1.5M$1M$500K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$2,001,622 · 1
By mechanism
R44$2,001,622 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsAdjuvantAdult19 Year OldAlabamaAntitumor EffectAnti-Tumor Immune ResponseArchivesAftercareBiologicalBiopsyBrain NeoplasmsBrain TissueCancer EtiologyCaregiversCellsChemotherapyChildChildhoodChildhood Brain NeoplasmChildhood Cancer MortalityChildhood GliomaClinical ResearchCommercialization
Grant awards (4)
Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$890,765
R44 · FY2023 · CA · contact PI
Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$1,625
R44 · FY2022 · CA · contact PI
Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$611,912
R44 · FY2020 · CA · contact PI
Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$497,320
R44 · FY2020 · CA · contact PI